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Abstract: Photodynamic therapy (PDT) is a minimally invasive therapeutic modality that has gained
great attention in the past years as a new therapy for cancer treatment. PDT uses photosensitizers that,
after being excited by light at a specific wavelength, react with the molecular oxygen to create reactive
oxygen species in the target tissue, resulting in cell death. Compared to conventional therapeutic
modalities, PDT presents greater selectivity against tumor cells, due to the use of photosensitizers
that are preferably localized in tumor lesions, and the precise light irradiation of these lesions. This
paper presents a review of the principles, mechanisms, photosensitizers, and current applications
of PDT. Moreover, the future path on the research of new photosensitizers with enhanced tumor
selectivity, featuring the improvement of PDT effectiveness, has also been addressed. Finally, new
applications of PDT have been covered.
Keywords: PDT mechanisms; new photosensitizers; PDT tumor treatment; antimicrobial PDT;
non-oncologic applications of PDT; PDT in medical devices
1. Introduction
1.1. History of Photodynamic Therapy
Light has been used in the treatment of several diseases since antiquity [1]. The ancient
civilizations, Egyptian, Indian, and Chinese, used the sunlight to treat various skin diseases,
such as psoriasis, vitiligo, and skin cancer [2]. Herodotus, a famous Greek physician known
as the father of heliotherapy, emphasized the importance of whole-body sun exposure for
the restoration of health. In the 18th and 19th centuries, in France, sunlight was used in the
treatment of several conditions, such as tuberculosis, rickets, scurvy, rheumatism, paralysis,
edema, and muscle weakness [3]. At the beginning of the 20th century, the importance of
light in the treatment of diseases was recognized, and the 1903 Nobel Prize in Physiology
or Medicine was awarded to Niels Finsen for his contribution in this field. Finsen found
that sunlight or light from a carbon arc lamp with a heat filter could be used to treat
lupus vulgaris, a tubercular condition of the skin. This discovery marked the beginning of
modern phototherapy [1,4,5].
Phototherapy describes the use of light in the treatment of a disease. However,
photochemotherapy requires the administration of a photosensitizing agent, which is
subsequently activated by light in the tissues, where the agent is localized. This form of
therapy also dates back over 3000 years, when the Indians and Egyptians used psoralens
from natural plants in the treatment of a variety of skin conditions [3,6].
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The concept of cell death induced by the interaction of light and chemicals has been
recognized for 100 years. In 1900, a German medical student, O. Raab, first reported cell
death induced by the interaction of light with chemicals. While working with Professor
H. von Tappeiner in Munich, he described the lethal effect that the combination of light
and acridine red had on protozoa [3,4,6]. In subsequent experiments, Raab demonstrated
that this lethal effect was greater than with acridine red alone, light alone, or acridine
red exposed to light and then added the protozoan. He reported that toxicity occurred as
a result of fluorescence caused by the transfer of energy from light to the chemical [6,7].
In the same year, the French neurologist J. Prime discovered that patients with epilepsy
who were treated with orally administered eosin developed dermatitis in areas exposed to
sunlight. Later, in 1903, H. von Tappeiner and A. Jesionek treated skin tumors with topical
applications of eosin and white light [3,4,6]. In 1904, H. von Tappeiner and A. Jodlbauer
identified that oxygen is an integral component in photosensitization reactions, and in 1907
they introduced the term “photodynamic action” to describe this phenomenon [1–3,6].
In 1841, H. Scherer first produced hematoporphyrin while investigating the nature
of blood. However, its fluorescent properties were not described until 1867, and this
substance was only named by hematoporphyrin in 1871. In 1911, W. Hausmann reported
the effects of hematoporphyrin and light on protozoa and blood cells, describing skin
reactions in a mice exposed to light after being administered with hematoporphyrin [3,4,6].
The first report of human photosensitization was in 1913, when F. Meyer-Betz injected
himself with 200 mg of hematoporphyrin to determine if similar effects could be induced
in humans. He described prolonged pain and swelling in light-exposed areas [2,3,6]. In
1960, R. Lipson and S. Schwartz initiated the concept of photodynamic therapy (PDT) at
the Mayo Clinic, discovering the cancer diagnostic and therapeutic effects by injecting
a hematoporphyrin derivative (HpD) [1]. In 1975, a significant breakthrough in PDT
occurred, when T. Dougherty reported that administration of HpD and its activation with
red light completely eradicated the growth of mammary tumor in mice. In the same year,
J. F. Kelly proved the elimination of bladder carcinoma in mice, by activating HpD with
light [4]. In 1976, another major event in the development of PDT occurred, when J. F.
Kelly and M. E. Snell proceeded to the first human study of the effects of PDT in bladder
cancer using HpD [3]. The use of this technique in the treatment of pathologies in the
gastrointestinal tract was first performed in 1984 by J. S. McCaughan, who used PDT to treat
patients with esophageal cancer. One year later, Y. Hayata used PDT to treat patients with
gastric carcinoma [3,4]. Dougherty and his coworkers also purified HpD and produced
Photofrin, which was the first photosensitizer molecule (PS) approved by the US Food and
Drug Administration (FDA) in 1995 for cancer treatment [2]. Since then, PDT has continued
to evolve and its clinical application was extended to other areas besides tumors treatment.
Dr. M. Weber, known as the pioneer of modern laser therapy, also applies PDT to treat
bacterial, viral, and parasitic diseases, named as antimicrobial PDT. The main advantage
of this new approach is to combat multiresistant pathogens. Dr. Weber developed the
Weberneedle® technology, which allows to apply highly focused and efficient lasers of
different wavelengths to intravenous, interstitial, and intra-articular irradiation [8,9].
1.2. Principles of PDT
PDT is based on the dynamic interaction between a PS, light with a specific wavelength,
and molecular oxygen, promoting the selective destruction of the target tissue [10]. The
PDT treatment consists in the administration of a PS (topically or intravenous), which
selectively accumulates in the tumor tissue (during a drug–light interval), followed by
subsequent exposition to an appropriate wavelength light (generally in the red spectral
region, λ ≥ 600 nm; Figure 1) [11]. The PS itself does not react with biomolecules; however,
illumination transfers energy from light to molecular oxygen, to generate reactive oxygen
species (ROS), such as singlet oxygen (1O2), superoxide radical (O2−•), hydroxyl radical
(HO•), and hydrogen peroxide (H2O2) [1]. These cytotoxic photoproducts start a cascade
of biochemical events, which can induce damage and death of the target tissue [11].
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Figure 1. Representation of the clinical application of PDT protocol for the treatment of a solid and
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2. Photodyna ic Reaction
PDT is a therapeutic modality based on the combination of three factors: PS, light
with a specific wavelength, and the presence of molecular oxygen [2]. The photodynamic
reaction begins ith the absorption of light by the PS in the target tissue, hich triggers
a series of photochemical reactions that lead to the generation of ROS [10]. After light
absorption, the PS is transformed from its ground state (singlet state, 1PS) to a short-lived,
electronically excited singlet state (a few nanoseconds or less, 1PS*) [2,4]. This excited state
is very unstable and can decay to the ground state, losing the excess of energy through
light emission (fluorescence) or heat production (internal conversion) [13]. However, the
singlet state can undergo intersystem crossing and progress to a more stable, long-lived,
electronically excited state (triplet state, 3PS*), through spin conversion of the electron in
the higher-energy orbital [13]. This excited state can decay to the ground state through light
emission (phosphorescence) or undergo two kinds of reactions [4]. The triplet state has a
longer lifetime (up to tens of microseconds), which allows sufficient time for direct transfer
of energy to molecular oxygen (O2). This energy transfer step leads to the formation of
singlet oxygen (1O2) and the fundamental state of the PS, called type II reaction [2,11]. The
singlet oxygen is extremely reactive and can interact with a large number of biological
substrates, inducing oxidative damage and ultimately cell death [11]. The type I reaction
can also occur if the excited state of the PS reacts directly with a substrate, such as cell
membrane or a molecule, and undergoes hydrogen atom abstraction or electron transfer
reactions, to yield free radicals and radical ions. These radicals react with molecular oxygen,
producing ROS, such as O2−•, HO•, and H2O2, which produce oxidative damage that can
lead to biological lesions [11]. Figure 2 shows the modified Jablonski diagram of the PDT
action mechanism.
The products resulting from type I and type II reactions are responsible for the effect
of cell death and therapeutic on PDT. Type I and type II reactions can occur simultaneously
and the ratio between these processes depends on the PS, substrate, oxygen concentration,
and binding affinity of the sensitizer to the substrate [2,4,13]. However, type II reaction is
predominant during PDT, and singlet oxygen is the primary cytotoxic agent responsible
for the biological effects [11]. The quantum yield of singlet oxygen formation is one of
the most important features of a PS and is determined by the quantum yield and lifetime
of its triplet excited state [10]. Due to the high reactivity and short half-life of the ROS,
only cells close to the area of the ROS production (areas where the PS is localized) are
directly affected by PDT. The extent of damage and cytotoxicity resulting from PDT is
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multifactorial, depending on the type of PS, its extracellular and intracellular location
and the total dose administered, the dose of light (light fluence) and the light fluence rate,
availability of oxygen, and the time between PS administration and light exposure [4]. PDT
of deeper and hypoxic tumors is more difficult due to the low oxygen concentration and
low light penetration into the tissue (light absorption by the PS and energy transfer to the
oxygen). On the other hand, more superficial and more oxygenated tumors allow greater
production of ROS and thus a more effective PDT treatment [14].
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3. PDT-Mediated Action Mechanisms
There are three main mechanisms by which PDT mediates tumor destruction (Figure 3) [4].
The ROS produced by PDT photochemical reactions can directly destroy tumor cells
by inducing apoptosis and necrosis. PDT can also cause the destruction of the tumor-
associated vasculature and the surrounding healthy vessels, leading to an interruption
of oxygen and nutrient supply and, consequently, to indirect cell death due to hypoxia.
Finally, PDT can induce an inflammatory response that activates an immune response
against the tumor cells [4,15]. The outcome of PDT depends on all of these mechanisms,
and the contribution of each one is determined by the treatment regime used [4,10].
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3.1. Apoptosis and Necrosis
Tumor destruction from PDT can occur by both programmed (apoptotic) pathways
and non-programmed (necrosis) pathways [11,16]. Generally, when high light intensity
is employed, the tumor cells are rapidly ablated by necrosis [11]. Necrosis is generally
described as a rapid and relatively broad mechanism of cell death, and it is characterized
by vacuolization of the cytoplasm and cell membrane breakdown, resulting in a local
inflammatory reaction due to the release of cytoplasmic content and pro-inflammatory
mediators in the extracellular medium [10].
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In contrast, apoptotic death may be initiated by PDT, generally when low light doses
are employed [11,16]. Apoptosis is described as a mechanism of programmed cell death that
is genetically encoded and energy dependent [10]. Morphologically, it is characterized by
chromatin condensation, cleavage of chromosomal DNA into internucleosomal fragments,
cell shrinkage, membrane wrinkling, and the formation of apoptotic bodies without plasma
membrane breakdown [2,7,10]. No effect or immune response is expected as no toxic
chemicals are leaked [11,16].
3.2. Vascular Mechanisms
In addition to the direct destruction of tumor cells, the application of PDT often also
leads to the destruction of the tumor microvasculature. Like tumor cells, endothelial
cells of the vascular system can concentrate PS to create free radicals when activated by
appropriate light. The disrupting of the vascular walls leads to the interruption of the
tumor’s feeding (i.e., oxygen and nutrients) and, consequently, to the death of the tumor
cells. PDT vascular effect has been shown to be very important for the long-term efficacy
of PDT [10]. PDT vascular effect can be greatly enhanced by using a short drug–light
interval (the time between systemic PS injection and light illumination) when the PS is
predominantly localized in the vasculature [1]. Selectivity in vascular PDT protocols is
achieved by the precise application of light on the tumor plus a safety margin of the
surrounding healthy tissue [10]. Vascular PDT has important advantages in comparison to
PDT protocols that require PS accumulation in the tumor cells: it uses photosensitizers that
clear rapidly from the organism and minimize skin photosensitivity, gives higher long-term
efficacy, and can be performed in one short session [10,17].
3.3. Immunological Mechanisms
For many years, PDT was considered a localized treatment, affecting only tumor cells
and tumor vasculature. More recently, numerous studies have demonstrated that PDT can
significantly influence the adaptive immune response in disparate ways, either through
stimulation or suppression of the immune response. The efficacy of PDT appears to be
dependent on the induction of antitumor immunity [10]. Long-term tumor control is a
combination of the direct effects of PDT on the lesion and its vasculature with upregulation
of the immune system [11].
Under certain conditions, PDT induces immunosuppression, which has been mainly
associated with reactions to topical treatments with high fluence rates and in large areas of
irradiation [10]. In contrast, non-topical PDT treatments are often described as immunos-
timulatory. The oxidative damage inflicted by PDT on the tumor stroma will eventually
result in cell death. When PDT induces necrosis of tumors and their vasculature, an im-
mune cascade is also initiated. The change in tissue integrity and homeostasis triggers an
acute inflammatory response initiated by the release of pro-inflammatory mediators, which
include various cytokines, growth factors, and proteins [10,11]. These mediators attract the
host’s innate immune cells, such as neutrophils, mast cells, macrophages, and dendritic
cells, which infiltrate the damaged tissue to restore homeostasis in the affected region [10].
Upon arrival, macrophages phagocytize PDT-damaged cancer cells and present proteins
from these tumors to CD4 helper T lymphocytes, which then activate CD8 cytotoxic T
lymphocytes [11]. These cytotoxic T cells can recognize and specifically destroy tumor cells
and can circulate throughout the body for long periods, ensuring a systemic antitumor
immune response [10].
4. PDT Essential Elements
4.1. Photosensitizers
Photosensitizers are key elements for PDT. Ideally, these molecules should accumulate
preferentially in the tumors, have a high singlet oxygen quantum yield, have low activity
in the absence of light, be quickly eliminated from the patient body, have amphiphilicity,
and have a light absorption peak between approximately 600 nm and 800 nm [18,19].
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There are a variety of molecular structures of photosensitizers that are currently used
in PDT, and it is possible to divide photosensitizers into three generations. The porfimer
sodium and the HpD are first-generation photosensitizers. The second-generation pho-
tosensitizers arise to overcome some drawbacks of the first-generation ones, related to
light absorption at a specific spectral region. Some examples of second-generation pho-
tosensitizers are the derivates of chlorins, bacteriochlorins, and phthalocyanines, which
can have a stronger action on the tumor regions due to their strong absorbance in the deep
red region, and consequently, increased light penetration. Finally, the third-generation
photosensitizers are molecules with improved selectivity for tumor regions, due to the
conjunction of the PS with targeting molecules or its encapsulation into carriers. Thus,
photosensitizers progressed towards the improvement of PDT specificity and efficacy.
Today, the functionalization of photosensitizers seems to be the best strategy to achieve
a high selectivity to the tumor regions, combining photosensitizers with biomolecules or
carriers [18–20]. Photosensitizers can be covalently bonded to several biomolecules, which
have affinity to tumors. These biomolecules include antibodies, proteins, carbohydrates,
and others. Photosensitizers can also be encapsulated into carriers, such as gold nanoparti-
cles, silica nanoparticles, quantum dots, carbon nanotubes, or others carriers, to guide the
photosensitizers to tumors [19,21–24].
Table 1 presents the most used photosensitizers in clinical PDT, including their trade
name and class, molecular formula, excitation wavelength, quantum yield, extinction
coefficient, and main applications [10,18,25–31]. A variety of photosensitizers under clinical
trials for approval in clinical PDT are presented in Table 2 [10,18,26,27,32–34].
Consensus protocol for conventional topical PDT recommends some lesion prepara-
tion to increase PS absorption and light penetration. The typical PDT topical treatment
protocol follows the next steps [35]:
- Wash the area to be treated with soap and water;
- Remove any residue and remaining oil with a gauze soaked in acetone or alcohol;
- Apply the PS evenly over the entire area to be treated. Apply a second layer of PS
after the first one has dried;
- Allow the PS to incubate for 0.5–4 h;
- Activate the PS with the appropriate light source;
- Wash the treated area with soap and water to remove any residual PS;
- Avoid any direct sunlight for 48 h;
- Repeat as needed in 2–3 weeks.
In dermatological indications, PDT is usually performed by topical application of PS,
in particular 5-aminolevulinic acid (5-ALA) or its ester methyl aminolevulinate (MAL) [35].
Three photosensitizers are currently approved for topical use in Europe: MAL Metvix®,
5-ALA Ameluz®, and 5-ALA AlaCare®. MAL Metvix® is used along with red light to treat
actinic keratosis, Bowen’s disease, and superficial basal cell carcinoma (3 h of drug-light
interval and 37–75 J/cm2 of total light dose). 5-ALA Ameluz® is used in combination with
red light for the treatment of mild and moderate actinic keratosis and superficial basal cell
carcinoma (3 h of drug-light interval and 37–200 J/cm2 of total light dose). MAL Metvix®
and 5-ALA Ameluz® are also used with daylight to treat moderate actinic keratosis (0.5 h
of drug-light interval and exposure during 2 h). 5-ALA AlaCare® is approved for the
treatment of mild actinic keratosis with red light (4 h of drug-light interval and 37 J/cm2 of
total light dose). A 20% formulation of 5-ALA Levulan® is approved in North America for
the treatment of actinic keratosis with blue light (14–18 h of drug-light interval and 10 J/cm2
of total light dose). Besides, topical PDT is highly recommended for the photorejuvenation
and the treatment of acne vulgaris, although these indications currently lack approval for
use and the protocols still need to be optimized [35–38].
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Table 1. Photosensitizers used in clinical PDT.


















C5H9NO3 630 - - Actinic keratosis
Levulan®
(porphyrin)
C5H9NO3 635 0.56 5.0 × 103 Actinic keratosis
Hexvix®
(porphyrin)
C11H21NO3 635 - <1.0 × 103 Bladder cancer
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(chlorine)
























C48H38F8N8O8S4 749 0.43 in ethanol 140 × 103 in ethanol Biliary tract cancer
Table 2. Photosensitizers under clinical trials for use in PDT.
Trade Name MolecularFormula
Excitation











662 0.52–0.62 3.42 × 104 Skin cancer
Photochlor®
(chlorins)
C39H48N4O4 664 0.48 in CH2Cl2






















4.2 × 104 in
methanol






solvent 8.85 × 10
4 Prostate cancer
A strategy that seems to be of great interest in the near future is to increase the
PDT selectivity through the development of activatable multifunctional photosensitizers,
which become active after receiving a biological or physical stimulus. Biological stimuli
include the physiological conditions associated with cancer, such as temperature, pH,
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and enzymatic activity. For example, the peptidic zipper-based PS was designed to react
under acidic conditions. Physical stimuli refer to an artificial agent activation, applying
magnetic or electric fields, ultrasounds, two-photon excitation, etc. [18,19]. For example,
electroporation can be used to support PDT (Figure 4). Electroporation is reported as an
effective method that could be used to increase the transport of a PS into the pathological
cells, which could lead to the increase of cytotoxicity and PDT efficacy. Several studies have
been performed over the years, using different photosensitizers, the clinically approved
Photofrin PS being the most relevant. The results, including a study performed with
human cancer cells, conclude, undoubtedly, that PDT with electroporation is an attractive
approach to cancer treatment, but detailed studies on the mechanisms of this approach are
still required [20,39].
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Very recently, the possibility of using transition metal coordination complexes or
organic fluorophores as efficient photosen itizers fo PDT has also be n reported. The
transition metal coordinator complexes, such as ruthenium(II) complexes, iridium(III) com-
plexes, and p lymetallic complexes, meet several basic needs for PDT. The mo t r levant
feature is their heavy-atom effect, which mediates strong spin–orbital coupling, providing
more time for the excited states to interact with molecular oxygen. Between other fea-
tures, it can be also be stated that they are easily synthetized, including the possibility of
fine-tuning their properties. The organic fluorophores, such as naphthalimides, xanthenes,
boron dipyrromethene (BODIPY), and cyanines, can also be designed as photosensitizers
for cancer PDT, with high light absorption at relatively long wavelengths and large molar
extinction coefficient. Organic fluorophore photosensitizers have low toxicity, good bio-
compatibility, and long triplet lifetimes, and their fluorescence emission can be used to
perform real-time monitoring during PDT treatment [40,41].
4.2. Light
PDT has been performed with various light sources, including lasers, incandescent
light, and laser-emitting diodes [42]. Laser light sources are usually expensive and require
the use of an optical system to expand the light beam for irradiation of a larger tissue
area. Non-laser light sources (e.g., conventional lamps) can be used with optical fibers
to specify the light wavelength for tissue irradiation. However, conventional lamps may
have thermal effects, which must be avoided in PDT. Finally, light-emitting diodes (LEDs)
have also been used in PDT as light sources. LEDs are less expensive, less hazardous,
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thermally non-destructive, and easily available in flexible arrays [43]. Light penetration
into tumor tissue is very complex, as it can be reflected, scattered, or absorbed. The
extent of these processes depends on the type of tissue and the wavelength of light [44].
Light absorption is mainly due to endogenous chromophores existing in tissues, such as
hemoglobin, myoglobin, and cytochromes, which can reduce the photodynamic process by
competing with PS in the absorption process [44,45]. Light absorption by tissues decreases
with increasing wavelength, so longer wavelengths of light (red light) penetrate more
efficiently through tissue. The region between 600 and 1200 nm is often called the “tissue
optical window” [12,44]. Shorter wavelengths (<600 nm) have less tissue penetration and
are more absorbed, resulting in increased skin photosensitivity. On the other hand, longer
wavelengths (>850 nm) do not have enough energy to excite oxygen in its state of singlet
and to produce enough reactive oxygen species. Therefore, the highest tissue permeability
occurs between 600 and 850 nm. This range, called the “phototherapeutic window,” is
predominantly used in PDT [10,12,18,20].
As light is an essential component of PDT, clinical efficacy is highly dependent on the
accuracy of its delivery to the target tissue and its dose, which translates into light fluence,
light fluence rate, light exposure time, and light delivery mode (single or fractionated) [12].
Light fluence is the total energy of exposed light across a sectional area of irradiated spot
and is expressed in J/cm2. Light fluence rate is the incident energy per second across a
sectional area of the irradiated spot and is expressed as W/cm2 [4,46,47].
Several studies have reported that low light fluence rates are advantageous for
PDT [48–50]. The main reason for the lower efficacy of PDT for high light fluence rates is
the oxygen depletion in tissues, which leads to a low photo-degradation of the PS. The
light fluence rate has also been shown to have an impact on the dominant mechanism of
cell death in the PDT. The use of low light fluence rates increases the selective apoptosis of
tumor cells, which is more desirable than inflammation and edema that usually occur with
the uncontrolled rupturing of cellular content in necrosis [51].
Another relevant light source for PDT is the natural light. The concept of daylight
PDT is based on the use of natural light instead of an artificial light source to treat skin
lesions, such as actinic keratosis. The main advantages of using daylight PDT are minimal
patient discomfort and shorter clinical visits (patients can complete their therapy at home).
Moreover, daylight PDT seems to be as effective as conventional PDT for actinic keratosis.
For this specific application, the patients expose the sites to daylight for 2 h, after 30 min
of PS application. The short PS incubation time in the daylight PDT, compared with
conventional PDT (1–3 h required), allows a smaller and more continuous PS activation,
leading to lower patient pain intensity associated with PDT [52,53].
4.3. Oxygen
The third key component in the PDT mechanism is molecular oxygen. Oxygen is
crucial for the production of ROS during PDT. Oxygen concentration in the tissues truly
affects the effectiveness of the PDT treatment. In fact, oxygen concentration can vary
significantly between different tumors and even between different regions of the same
tumor, depending on the density of the vasculature. Especially in deeper solid tumors,
often characterized by their anoxic microenvironment, lack of oxygen can be a limiting
factor. As mentioned above, the irradiation of the tumor with a high light fluence rate can
lead to a temporary local oxygen depletion. This leads to interruption of ROS production
and reduced treatment effectiveness. Oxygen depletion occurs when the rate of oxygen
consumption by the photodynamic reaction is greater than the rate of oxygen diffusion
in the irradiated area. In addition, PDT can cause occlusion of the tumor vasculature,
reducing blood flow to the tumor tissue, further increasing hypoxia [10,26,46].
Real-time measurement of the tissue oxygen levels, before and during PDT, is one of
the main challenges in the near future. This allows to optimize the PDT therapeutic result
by adjusting the light fluence rate (increasing the irradiation time to maintain the total
light dose) or using fractional light dose. Several sensors have been used to monitor the
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oxygen level in biological media, using imaging agents. However, the combination of these
imaging agents with PS has been hardly reported [18]. Other methods to increase oxygen
availability in the tumor have been tested: indirect introduction of oxygen and direct
introduction of oxygen. One indirect way to increase oxygen concentration in tumor cells
is using catalase enzyme to decompose the intracellular hydrogen peroxide into oxygen.
The direct delivery of oxygen into tumors is achieved by using oxygen carriers, such as
perfluorocarbons and hemoglobin, commonly used to overcome tumor hypoxia in the PDT
procedure [37].
5. Advantages and Limitations of PDT
PDT has several advantages over conventional approaches to cancer treatment. First-
generation photosensitizers cause increased skin photosensitivity. However, PDT has no
long-term side effects when correctly used. It is less invasive than surgical procedures
and can be performed on an outpatient basis. In addition to the tumor itself, PDT can
also destroy the vasculature associated with it, greatly contributing to tumor death [54].
PDT can be applied directly and accurately in the target tissue, due to its dual selectivity.
The two main factors that contribute to the selectivity of PDT are the intrinsic capacity of
some photosensitizers to preferentially accumulate in tumor tissue and light irradiation
exclusively in the target tissue [10,54]. The selective accumulation of the PS in the tumor
is facilitated in the case of topical application, since PS is applied directly and only to the
lesions to be treated. When PS is given intravenously, it needs to remain in circulation long
enough to reach and accumulate in the tumor [10]. Furthermore, PDT can be repeated sev-
eral times in the same location, unlike radiation. There is little or no scarring after healing.
Finally, it usually costs less than other therapeutic modalities in cancer treatment [54,55].
Like every therapeutic modalities, PDT also has some limitations. The photodynamic
effect occurs selectively in the irradiated site, which makes its use in disseminated metas-
tases very difficult with the currently available technology [54]. Tissue oxygenation is
crucial for the photodynamic effect to occur, so tumors surrounded by necrotic tissue or
dense tumor masses can lead to ineffective PDT. Finally, the accuracy of target tissue irradi-
ation is the most important point when considering PDT as a treatment option. Therefore,
deep tumors (not easily accessible without surgical intervention) are difficult to treat due
to the low penetration of visible light into the tissue [54,56]. The main advantages and
limitations of PDT are summarized in Table 3.





VUsable in outpatient basis
VCancer selectivity




XTreatment efficacy dependent on accuracy of
tumor light irradiation
XTissue oxygenation is crucial for the
photodynamic effect
XVery difficult to treat metastatic cancers with
current technology
6. Applications of PDT
PDT is a minimally invasive procedure that is clinically used in the treatment of several
oncologic human diseases, such as skin, esophageal, head and neck, lung, and bladder
cancers [57]. However, PDT also has several non-oncologic applications [58], including the
treatment of non-cancerous human diseases, such as dermatologic (acne [59], warts [60],
photoaging [61], psoriasis [62], vascular malformations [63], hirsutism [64], keloid [50], and
alopecia areata [65]), ophthalmologic (central serous chorioretinopathy [66] and corneal
neovascularization [67]), cardiovascular (atherosclerosis [68] and esophageal varix [69]),
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dental (oral lichen planus [70]), neurologic (Alzheimer’s disease [71]), skeletal (rheumatoid
arthritis [72]), and gastrointestinal (Crohn’s disease [73]).
An extension of PDT procedure can be the inactivation of viruses and microorganisms,
including bacteria, yeasts, and fungi, named as photodynamic inactivation of microorgan-
isms (PDI). The viruses or microorganisms are inactivated by combining non-toxic dyes
(photosensitizers) with harmless visible light. PDI can be used as an alternative to the use
of antibiotics and antiviral drugs that usually cause resistance. The application of PDI is
possible in several areas, including human and veterinary medicine, agro-food, wastewater
treatment, and biosafety. However, PDI in the treatment of infections is easier to perform
in vitro, compared with its clinical applicability, due to the low tissue penetration depth of
visible light. Light applied intravenously can be a solution during the clinical treatment of
infections. Very recently, the use of the PDT procedure to treat patients with COVID-19 has
also been discussed [8,57,74–81].
Dr. M. Weber et al. [8] performed a study to evaluate if the PDT procedure with
Riboflavin (also known as vitamin B2) and blue light can be used effectively as a therapy for
patients infected with acute COVID-19. The study used COVID-19-positive patients who
received PDT therapy and COVID-19-positive patients who received conventional care. The
patients that received PDT treatment showed significant improvement in clinical symptoms
and viral load within 5 days. The control patients had no significant improvement in clinical
symptoms or viral load within 5 days. The results prove the potential of PDT procedure
to treat patients infected with COVID-19 virus at an early infection stage and with mild
to moderate clinical symptoms. This new application of PDT procedure can prevent
hospitalization and intensive care treatments.
Finally, PDT can be implemented in a medical device, e.g., endoscopic capsule. In
2016, G. Tortora et al. [82] developed an ingestible capsule for light delivery in PDT
treatment of Helicobacter pylori infection. Helicobacter pylori bacterium is known to be
photosensitive without the exogenous assumption of photosensitizers. This bacterium can
be killed by exciting the photosensitizers naturally present in it with the appropriate light
wavelength. The capsule with 27 mm length and 14 mm diameter has been equipped with
8 LEDs positioned on an electronic board with a magnetic switch (to turn on the capsule’s
power) and a battery. The capsule light-emitting module was dimensioned considering the
required light necessary to kill the bacterium, with blue (405 nm) and red (625 nm) lights.
In 2018, J. A. Rodrigues et al. [26,83] studied the photodynamic activity of the mTHPC
(Foscan®) on RKO and HCT-15 cell lines to implement PDT in autonomous medical devices,
such as endoscopic capsules for clinical treatment of several gastrointestinal tract tumors.
Figure 5 envisages the integration of PDT in the endoscopic capsule. Due to the endoscopic
capsule dimensions and battery life, the light fluence and fluence rate of the red light must
be minimized to reduce the PDT treatment time. The experimental results showed that
a small amount of mTHPC (0.15 mg/kg) and light fluence (5–20 J/cm2) is sufficient to
obtain significant photodynamic activity. An array of LEDs with peak transmittance at
652 nm was used in the in vitro PDT assays. The experimental results show that decreased
cell viability (down to 30%) can be obtained for 1–5 µg/mL of mTHPC concentrations
and 2.5 J/cm2 of light fluence. The use of a minimum light fluence (2.5 J/cm2) and light
fluence rate (11 mW/cm2) allowed to reduce the treatment time to just 3 min and 47 s.
The PDT endoscopic capsule was designed with two functional sides. The round side is
compound of the conventional optical system of the endoscopic capsule, consisting of the
CMOS image sensor, four white LEDs, and focal lenses, and the planar side constitutes the
therapeutic module, composed of a red light source (array of 8 SMD red LEDs with total
fluence rate of 14 mW/cm2) and a magnetic switch for turning the red light on and off.
This capsule has magnetic locomotion control, for immobilization of the capsule during
the treatment time, and is 31 mm in length and 14 mm in diameter. mTHPC-mediated
PDT, using a light fluence of 2.5 J/cm2 and fluence rate of 14 mW/cm2, reduces the PDT
treatment time to approximately 3 min. Faster treatment requires less battery capacity and
therefore fewer capsules.
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also addressed in this paper, including their future trends. Photosensitizers are evolving
to ards increasing the P T efficacy and selectivity, and any possibilities are currently
under research. One strategy to increase PDT selectivity involves the development of
multifunctional photosensitizers that can be activated by a biological or physical stimulus.
PDT has been increasingly used in many applications, such as destroying tumor tis-
sues, bacteria, fungi, and viruses (including COVID-19). Moreover, PDT can be integrated
in medical devices. A light delivery capsule has been developed for mTHPC-mediated
PDT treatment of several gastrointestinal tract tumors. The good photodynamic response
at low light fluence and low light fluence rate allows to reduce the treatment time to a few
minutes and thus integrate the PDT in autonomous medical devices, such as endoscopic
capsules of very small dimensions, to provide them with an advanced therapeutic function.
The interdisciplinary uniqueness of PDT inspires physicists, chemists, biologists, and
physicians, and its further development and discovery of new applications will only be
limited by their enormous imagination.
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K.; Kulbacka, J. Photodynamic therapy—Mechanisms, photosensitizers and combinations. Biomed. Pharmacother. 2018, 106,
1098–1107. [CrossRef]
21. Duse, L.; Agel, M.R.; Pinnapireddy, S.R.; Schäfer, J.; Selo, M.A.; Ehrhardt, C.; Bakowsky, U. Photodynamic therapy of ovarian
carcinoma cells with curcumin-loaded biodegradable polymeric nanoparticles. Pharmaceutics 2019, 11, 282. [CrossRef]
22. Chizenga, E.P.; Abrahamse, H. Nanotechnology in modern photodynamic therapy of cancer: A review of cellular resistance
patterns affecting the therapeutic response. Pharmaceutics 2020, 12, 632. [CrossRef]
23. Li, T.; Yan, L. Functional polymer nanocarriers for photodynamic therapy. Pharmaceuticals 2018, 11, 133. [CrossRef]
24. Montaseri, H.; Kruger, C.A.; Abrahamse, H. Inorganic nanoparticles applied for active targeted photodynamic therapy of breast
cancer. Pharmaceutics 2021, 13, 296. [CrossRef] [PubMed]
25. Kataoka, H.; Nishie, H.; Hayashi, N.; Tanaka, M.; Nomoto, A.; Yano, S.; Joh, T. New photodynamic therapy with next-generation
photosensitizers. Ann. Transl. Med. 2017, 5, 183. [CrossRef] [PubMed]
26. Rodrigues, J.A.O. Therapy in Invasive Medical Devices with Image. Ph.D. Thesis, University of Minho, Braga, Portugal, 2019.
27. Yano, S.; Hirohara, S.; Obata, M.; Hagiya, Y.; Ogura, S.; Ikeda, A.; Kataoka, H.; Tanaka, M.; Joh, T. Current states and future views
in photodynamic therapy. J. Photochem. Photobiol. C Photochem. Rev. 2011, 12, 46–67. [CrossRef]
28. Ormond, A.; Freeman, H. Dye sensitizers for photodynamic therapy. Materials 2013, 6, 817–840. [CrossRef]
29. Chen, J.; Fan, T.; Xie, Z.; Zeng, Q.; Xue, P.; Zheng, T.; Chen, Y.; Luo, X.; Zhang, H. Advances in nanomaterials for photodynamic
therapy applications: Status and challenges. Biomaterials 2020, 237, 119827. [CrossRef] [PubMed]
30. FDA. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208081s000lbl.pdf (accessed on
3 August 2021).
Pharmaceutics 2021, 13, 1332 14 of 16
31. Reinhold, U.; Petering, H.; Dirschka, T.; Rozsondai, A.; Gille, J.; Kurzen, H.; Ostendorf, R.; Ebeling, A.; Stocker, M.; Radny, P.
Photodynamic therapy with a 5-ALA patch does not increase the risk of conversion of actinic keratoses into squamous cell
carcinoma. Exp. Dermatol. 2018, 27, 1399–1402. [CrossRef]
32. Privalov, V.A.; Lappa, A.V.; Kochneva, E.V. Five years experience of photodynamic therapy with new chlorin photosensitizer. In
Therapeutic Laser Applications and Laser-Tissue Interactions II, Proceedings of the European Conference on Biomedical Optics, Munich,
Germany, 12–16 June 2005; Proceedings SPIE 5863; SPIE: Bellingham, WA, USA, 2005; p. 586310.
33. Nyman, E.S.; Hynninen, P.H. Research advances in the use of tetrapyrrolic photosensitizers for photodynamic therapy. J.
Photochem. Photobiol. B Biol. 2004, 73, 1–28. [CrossRef]
34. O’Connor, A.E.; Gallagher, W.M.; Byrne, A.T. Porphyrin and nonporphyrin photosensitizers in oncology: Preclinical and clinical
advances in photodynamic therapy. Photochem. Photobiol. 2009, 85, 1053–1074. [CrossRef]
35. Ozog, D.M.; Rkein, A.M.; Fabi, S.G.; Gold, M.H.; Goldman, M.P.; Lowe, N.J.; Martin, G.M.; Munavalli, G.S. Photodynamic
therapy: A clinical consensus guide. Dermatol. Surg. 2016, 42, 804–827. [CrossRef]
36. Morton, C.A.; Szeimies, R.-M.; Sidoroff, A.; Braathen, L.R. European guidelines for topical photodynamic therapy part 1:
Treatment delivery and current indications—Actinic keratoses, Bowen’s disease, basal cell carcinoma. J. Eur. Acad. Dermatol.
Venereol. 2013, 27, 536–544. [CrossRef] [PubMed]
37. Morton, C.A.; Szeimies, R.-M.; Basset-Séguin, N.; Calzavara-Pinton, P.G.; Gilaberte, Y.; Hædersdal, M.; Hofbauer, G.F.L.; Hunger,
R.E.; Karrer, S.; Piaserico, S.; et al. European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 2:
Emerging indications—Field cancerization, photorejuvenation and inflammatory/infective dermatoses. J. Eur. Acad. Dermatol.
Venereol. 2020, 34, 17–29. [CrossRef]
38. Morton, C.A.; Szeimies, R.-M.; Basset-Seguin, N.; Calzavara-Pinton, P.; Gilaberte, Y.; Hædersdal, M.; Hofbauer, G.F.L.; Hunger,
R.E.; Karrer, S.; Piaserico, S.; et al. European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1:
Treatment delivery and established indications—Actinic keratoses, Bowen’s disease and basal cell carcinomas. J. Eur. Acad.
Dermatol. Venereol. 2019, 33, 2225–2238. [CrossRef] [PubMed]
39. Wezgowiec, J.; Derylo, M.B.; Teissie, J.; Orio, J.; Rols, M.-P.; Kulbacka, J.; Saczko, J.; Kotulska, M. Electric field-assisted delivery of
photofrin to human breast carcinoma cells. J. Membr. Biol. 2013, 246, 725–735. [CrossRef] [PubMed]
40. Zhao, X.; Liu, J.; Fan, J.; Chao, H.; Peng, X. Recent progress in photosensitizers for overcoming the challenges of photodynamic
therapy: From molecular design to application. Chem. Soc. Rev. 2021, 50, 4185–4219. [CrossRef]
41. Soliman, N.; Sol, V.; Ouk, T.-S.; Thomas, C.M.; Gasser, G. Encapsulation of a Ru(II) polypyridyl complex into polylactide
nanoparticles for antimicrobial photodynamic therapy. Pharmaceutics 2020, 12, 961. [CrossRef]
42. Yanovsky, R.L.; Bartenstein, D.W.; Rogers, G.S.; Isakoff, S.J.; Chen, S.T. Photodynamic therapy for solid tumors: A review of the
literature. Photodermatol. Photoimmunol. Photomed. 2019, 35, 295–303. [CrossRef] [PubMed]
43. Chen, D.; Zheng, H.; Huang, Z.; Lin, H.; Ke, Z.; Xie, S.; Li, B. Light-emitting diode-based illumination system for in vitro
photodynamic therapy. Int. J. Photoenergy 2012, 2012, 1–6. [CrossRef]
44. Yoon, I.; Li, J.Z.; Shim, Y.K. Advance in photosensitizers and light delivery for photodynamic therapy. Clin. Endosc. 2013, 46, 7.
[CrossRef]
45. Allison, R.R.; Sibata, C.H. Oncologic photodynamic therapy photosensitizers: A clinical review. Photodiagnosis Photodyn. Ther.
2010, 7, 61–75. [CrossRef]
46. Kinsella, T.J.; Colussi, V.C.; Oleinick, N.L.; Sibata, C.H. Photodynamic therapy in oncology. Expert Opin. Pharmacother. 2001, 2,
917–927. [CrossRef]
47. Chilakamarthi, U.; Giribabu, L. Photodynamic therapy: Past, present and future. Chem. Rec. 2017, 17, 775–802. [CrossRef]
48. Rezzoug, H.; Bezdetnaya, L.; A’amar, O.; Merlin, J.L.; Guillemin, F. Parameters affecting photodynamic activity of Foscan® or
metatetra(hydroxyphenyl)chlorin (mTHPC) in vitro and in vivo. Lasers Med. Sci. 1998, 13, 119–125. [CrossRef]
49. Coutier, S.; Mitra, S.; Bezdetnaya, L.N.; Parache, R.M.; Georgakoudi, I.; Foster, T.H.; Guillemin, F. Effects of fluence rate on cell
survival and photobleaching in meta-tetra-(hydroxyphenyl)chlorin–photosensitized colo 26 multicell tumor spheroids. Photochem.
Photobiol. 2001, 73, 297. [CrossRef]
50. Bruscino, N.; Lotti, T.; Rossi, R. Photodynamic therapy for a hypertrophic scarring: A promising choice. Photodermatol. Photoim-
munol. Photomed. 2011, 27, 334–335. [CrossRef] [PubMed]
51. Hartl, B.A.; Hirschberg, H.; Marcu, L.; Cherry, S.R. Characterizing low fluence thresholds for in vitro photodynamic therapy.
Biomed. Opt. Express 2015, 6, 770. [CrossRef] [PubMed]
52. Nguyen, M.; Sandhu, S.; Sivamani, R. Clinical utility of daylight photodynamic therapy in the treatment of actinic keratosis—A
review of the literature. Clin. Cosmet. Investig. Dermatol. 2019, 12, 427–435. [CrossRef]
53. Morton, C.A.; Braathen, L.R. Daylight photodynamic therapy for actinic keratoses. Am. J. Clin. Dermatol. 2018, 19, 647–656.
[CrossRef]
54. Calixto, G.; Bernegossi, J.; de Freitas, L.; Fontana, C.; Chorilli, M. Nanotechnology-based drug delivery systems for photodynamic
therapy of cancer: A review. Molecules 2016, 21, 342. [CrossRef]
55. Dos Santos, A.F.; De Almeida, D.R.Q.; Terra, L.F.; Baptista, M.S.; Labriola, L. Photodynamic therapy in cancer treatment—An
update review. J. Cancer Metastasis Treat. 2019, 2019. [CrossRef]
56. Lange, N.; Szlasa, W.; Saczko, J.; Chwiłkowska, A. Potential of cyanine derived dyes in photodynamic therapy. Pharmaceutics
2021, 13, 818. [CrossRef]
Pharmaceutics 2021, 13, 1332 15 of 16
57. Plaetzer, K.; Berneburg, M.; Kiesslich, T.; Maisch, T. New applications of photodynamic therapy in biomedicine and biotechnology.
Biomed. Res. Int. 2013, 2013, 1–3. [CrossRef]
58. Yoo, S.W.; Oh, G.; Ahn, J.C.; Chung, E. Non-oncologic applications of nanomedicine-based phototherapy. Biomedicines 2021, 9,
113. [CrossRef] [PubMed]
59. Calzavara-Pinton, P.G.; Rossi, M.T.; Aronson, E.; Sala, R.; The Italian Group for Photodynamic Therapy. A retrospective analysis
of real-life practice of off-label photodynamic therapy using methyl aminolevulinate (MAL-PDT) in 20 Italian dermatology
departments. Part 1: Inflammatory and aesthetic indications. Photochem. Photobiol. Sci. 2013, 12, 148. [CrossRef] [PubMed]
60. Stender, I.-M.; Na, R.; Fogh, H.; Gluud, C.; Wulf, H.C. Photodynamic therapy with 5-aminolaevulinic acid or placebo for
recalcitrant foot and hand warts: Randomised double-blind trial. Lancet 2000, 355, 963–966. [CrossRef]
61. Shin, H.T.; Kim, J.H.; Shim, J.; Lee, J.H.; Lee, D.Y.; Lee, J.H.; Yang, J.M. Photodynamic therapy using a new formulation of
5-aminolevulinic acid for wrinkles in Asian skin: A randomized controlled split face study. J. Dermatol. Treat. 2015, 26, 246–251.
[CrossRef]
62. Choi, Y.M.; Adelzadeh, L.; Wu, J.J. Photodynamic therapy for psoriasis. J. Dermatol. Treat. 2015, 26, 202–207. [CrossRef]
63. Jerjes, W.; Upile, T.; Hamdoon, Z.; Mosse, C.A.; Akram, S.; Morley, S.; Hopper, C. Interstitial PDT for vascular anomalies. Lasers
Surg. Med. 2011, 43, 357–365. [CrossRef]
64. Comacchi, C.; Bencini, P.L.; Galimberti, M.G.; Cappugi, P.; Torchia, D. Topical photodynamic therapy for idiopathic hirsutism and
hypertrichosis. Plast. Reconstr. Surg. 2012, 129, 1012e–1014e. [CrossRef]
65. Linares-González, L.; Ródenas-Herranz, T.; Sáenz-Guirado, S.; Ruiz-Villaverde, R. Successful response to photodynamic therapy
with 5-aminolevulinic acid nanoemulsified gel in a patient with universal alopecia areata refractory to conventional treatment.
Dermatol. Ther. 2020, 33, e13416. [CrossRef]
66. van Dijk, E.H.C.; Fauser, S.; Breukink, M.B.; Blanco-Garavito, R.; Groenewoud, J.M.M.; Keunen, J.E.E.; Peters, P.J.H.; Dijkman,
G.; Souied, E.H.; MacLaren, R.E.; et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser
treatment in patients with chronic central serous chorioretinopathy. Ophthalmology 2018, 125, 1547–1555. [CrossRef]
67. Díaz-Dávalos, C.D.; Carrasco-Quiroz, A.; Rivera-Díez, D. Neovascularization corneal regression in patients treated with photody-
namic therapy with verteporfin. Rev. Med. Inst. Mex. Seguro Soc. 2016, 54, 164–169.
68. Houthoofd, S.; Vuylsteke, M.; Mordon, S.; Fourneau, I. Photodynamic therapy for atherosclerosis. The potential of indocyanine
green. Photodiagn. Photodyn. Ther. 2020, 29, 101568. [CrossRef] [PubMed]
69. Li, C.Z.; Cheng, L.F.; Wang, Z.Q.; Gu, Y. Attempt of photodynamic therapy on esophageal varices. Lasers Med. Sci. 2009, 24,
167–171. [CrossRef] [PubMed]
70. Cosgarea, R.; Pollmann, R.; Sharif, J.; Schmidt, T.; Stein, R.; Bodea, A.; Auschill, T.; Sculean, A.; Eming, R.; Greene, B.; et al.
Photodynamic therapy in oral lichen planus: A prospective case-controlled pilot study. Sci. Rep. 2020, 10, 1667. [CrossRef]
[PubMed]
71. Lee, B., II; Suh, Y.S.; Chung, Y.J.; Yu, K.; Park, C.B. Shedding light on Alzheimer’s β-amyloidosis: Photosensitized methylene blue
inhibits self-assembly of β-amyloid peptides and disintegrates their aggregates. Sci. Rep. 2017, 7, 7523. [CrossRef]
72. Gallardo-Villagrán, M.; Leger, D.Y.; Liagre, B.; Therrien, B. Photosensitizers used in the photodynamic therapy of rheumatoid
arthritis. Int. J. Mol. Sci. 2019, 20, 3339. [CrossRef] [PubMed]
73. Favre, L.; Borle, F.; Velin, D.; Bachmann, D.; Bouzourene, H.; Wagnieres, G.; van den Bergh, H.; Ballabeni, P.; Gabrecht, T.; Michetti,
P.; et al. Low dose endoluminal photodynamic therapy improves murine T cell-mediated colitis. Endoscopy 2011, 43, 604–616.
[CrossRef]
74. Huang, L.; Dai, T.; Hamblin, M.R. Antimicrobial photodynamic inactivation and photodynamic therapy for infections. Methods
Mol. Biol. 2010, 635, 155–173. [CrossRef]
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